Krystal Biotech, Inc. (KRYS)

177.78 -4.94 (-2.70%) 收市：04:00PM EDT

Krystal Biotech, Inc.

2100 Wharton Street
Suite 701
Pittsburgh, PA 15203
United States
412 586 5830
https://www.krystalbio.com

版塊: Healthcare
行業: Biotechnology
全職員工: 229

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Krish S. Krishnan M.B.A., M.S.	Founder, Chairman, President & CEO	1.32M	無	1965
Ms. Suma M. Krishnan	Founder, President of R&D and Director	895.33k	無	1965
Ms. Kathryn A. Romano	Executive VP & Chief Accounting Officer	614.87k	2.35M	1982
Mr. John Thomas	General Counsel & Corporate Secretary	無	無	無
Mr. John Karakkal	Vice President of North American Sales & Marketing	無	無	無
Ms. Christine Wilson	Head of U.S. Sales and Marketing	無	無	無
Dr. Stephane Paquette Ph.D.	Vice President of Corporate Development	無	無	無
Mr. Josh Suskin	Director of Human Resources & Operations	無	無	無
Mr. Laurent Goux	Senior VP & GM of Europe	無	無	無
Mr. David Chien	Senior Vice President of Clinical Development	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

公司管治

截至 2024年6月1日 止，Krystal Biotech, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：3；董事會：9；股東權利：8；現金賠償：5。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。